GMMG-HD7 Clinical Trial for Patients With Multiple Myeloma

(5:32)

Isatuximab, Lenalidomide, Bortezomib, and Dex for Newly-Diagnosed Multiple Myeloma: GMMG-HD7

(10:37)

An update on GMMG HD7: Isa-RVd vs RVd \u0026 lenalidomide-isatuximab vs lenalidomide maintenance in NDMM

(49)

Addition of Isatuximab to RVd As Induction Therapy for Newly-Diagnosed, Transplant-Eligible MM Pts

(4:24)

Four-year follow-up of GMMG-CONCEPT: efficacy of Isa-KRd in high-risk newly diagnosed myeloma

(1:28)

Isatuximab, lenalidomide, bortezomib and dexamethasone as induction therapy for NDMM patients

(4:29)

Phase III trial of RVd induction with or without isatuximab in newly diagnosed myeloma

(6:37)

Terapia d'induzione nel MM, update dal GMMG-HD7 trial

(7:28)

Where is Myeloma Treatment Headed? Let’s Talk Quadruplets (4-Drug Combinations) | Dr. Joseph Mikhael

(9:53)

OncoAlert Session Round Up at ASH 24 in Multiple Myeloma: pharmacologic Therapies: Refining Evidence

(9:16)

The safety and efficacy of isatuximab, bortezomib, lenalidomide, and dexamethasone in NDMM

(50)

GMMG-CONCEPT: Isa-KRd in front-line treatment of high-risk myeloma

(5:17)

Optimizing the treatment of transplant-eligible NDMM: using quadruplets in induction \u0026 consolidation

(1:5)

First results of the GMMG-CONCEPT trial for multiple myeloma

(4:24)

ASH 2024 Myeloma Update with Dr. Rakesh Popat

(38:4)

Adding Isatuximab to Standard RVD May Improve Outcomes for Myeloma Patients | Elias Mai, MD | #ASH24

(7:4)

IACH Journal Club

(54:7)

An update on antibody-based treatment approaches in multiple myeloma

(2:33)

Current treatment landscape of newly diagnosed multiple myeloma

(2:11)